AUPH
Full HouseAurinia Pharmaceuticals Inc. · Healthcare · Canada · $2.2B cap · $14.5M/day traded
$16.21 +0.0% · close 12 Nov · scored 13 Nov
Full House: Strong business, sensible price, and the market agrees.
As of 13 Nov 2026, the MoatMap Score for Aurinia Pharmaceuticals Inc. (AUPH) is 96/100, ranked against 25,000+ stocks in 38 markets (Quality 84, Value 60, Momentum 61, each scored against its sector).
Does the score work? Each tenth of the ranking, tracked monthly. See the record →
ABOUT AURINIA PHARMACEUTICALS INC.
Read
Aurinia Pharmaceuticals Inc. is a Canadian pharmaceutical company primarily focused on developing and commercializing therapies for autoimmune diseases. Its competitive moat is centered around LUPKYNIS (voclosporin), a proprietary drug approved for lupus nephritis, addressing a high unmet medical need and offering a significant market opportunity. Aurinia operates as a commercial-stage biotech, dedicated to expanding the market presence of its specialized therapeutic.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 134.0M | 175.5M | 235.1M | 283.1M | 28.3% | 321.7M | 330.2M | 388.7M | 17.2% |
| EPS | -0.76 | -0.54 | 0.04 | 2.14 | 5250.0% | 2.28 | — | — | — |
| Shares | 142.3M | 143.8M | 140.9M | 132.3M | -7.0% | 134.0M | — | — | — |
| Debt | 8.1M | 97.6M | 79.4M | 74.8M | 109.9% | 58.7M | — | — | — |
| Equity | 405.4M | 378.0M | 377.5M | 581.3M | 12.8% | — | — | — | — |
| Op CF | -79.5M | -33.5M | 44.4M | 135.7M | 205.6% | 177.2M | — | — | — |
| Inv CF | -60.6M | -6.7M | 39.3M | -32.8M | — | — | — | — | — |
| Fin CF | 2.4M | -5.1M | -49.1M | -106.1M | — | — | — | — | — |
No clear trend: not near its 52-week low, and not in a steady uptrend.
Calmer than 62% of stocks we rank over the past year (volatility 35% a year).
How this is worked out
The Price check reads only the chart, the price side of the Momentum score in words; it is not the MoatMap Score.
- Still falling: It set a new 52-week low in the last two weeks, after a deep fall.
- Finding a floor: It fell hard, but has set no new low for more than two weeks.
- Turning up: It has climbed off its low and is back above a rising 50-day average.
- In an uptrend: It is near its 52-week high and above its 200-day average.
- No clear trend (this stock): None of the above: no recent deep fall and no steady climb.
- No read yet: Not enough price history yet: it needs a year of trading.
In past US falls, waiting for Turning up cut the chance of another 20% drop from 42% to 33%. Returns were no better, and 33% of turns failed.
The exact rules
Still falling is a new 52-week low in the last two weeks, at least 25% below the high, with the low set after the high. Finding a floor is the same fall with no new low in the last two weeks. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average, with the 50-day average above the 200-day, and within 15% of the high. No clear trend is everything else. No read yet is under 252 trading days of history, or missing data. A new state shows once it has held for three trading days.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AUPH are excluded.
| Ticker | Company | Mkt Cap | Score |
|---|---|---|---|
| AUPH | Aurinia Pharmaceuticals Inc.(you) | $2.2B | 96 |
| ABCL | AbCellera Biologics Inc. | $3.8B | 30 |
| HELP | Cybin D/B/A Helus Pharma | $744M | 38 |
| XENE | Xenon Pharmaceuticals Inc. | $3.4B | 12 |
| BHC | Bausch Health Companies Inc. | $2.4B | 96 |
| EPRX.TO | Eupraxia Pharmaceuticals Inc. | $452M | 25 |
| EBM.V | Eastwood Bio-Medical Canada Inc. | $92M | 48 |
| DHT-UN.TO | DRI Healthcare Trust | $743M | 93 |
| GUD.TO | Knight Therapeutics Inc. | $814M | 82 |
| MSLE | Satellos Bioscience Inc. | $136M | 17 |
Peer medians: ROE -31.6% · P/E 19.5x · Gross margin 50.7%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.